Document 4QbgQyzJNJNdwbVMDBmaOGaDR

Message From: Sent: To: Subject: Lynn, Tricia [/0=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=D8747BA49CDE485EA4AC58DBF09C3DCD-TRICIA SLUSSER] 9/25/2017 7:22:30 PM [Z Z Z I a ZZTMJ FW: For Review: Pharmaceutical Times (Ken Fagerman) RE: Reducing Pharmaceutical Footprint (9/25) Hi Ken-- I'm stepping in for my colleague, Enesta Jones, who is out today. For attribution to "an EPA spokesperson:" EPA cannot comment on this research. Best, Tricia Tricia Lynn Office of Public Affairs U.S. EPA Office: 202.564.2615 ---- Original Message----- From: Jones, Enesta Sent: Friday, Septe;-m---b--e--r--2--2--,--2--0--1--7---2--:-0--3--,PM To: Ken Fagerman [ Ex. 6 j Cc: Lynn, Tricia <iynn.fricia(g)epa.gov>; Jones, Enesta <jones.Enesta(g)epa.gov> Subject: Re: Pharmaceuticals Hi Ken, we will need until Monday to be responsive. My colleague, Tricia Lynn, copied here, will be in touch since I'm out on Monday and Tuesday of next week. Thanks for understanding and have a great weekend. On Sep 20, 2017, at 12:08 PM, Ken Fagerman <j_____ Ex. 6______jwrote: I am ready to submit with some final edits. Would you be able to provide me with something by the end of the week. Ken Fagerman Sent from my iPhone > On Sep 20, 2017, at 11:39 AM, Jones, Enesta clones.Enesta@epa.gov> wrote: > > Hi Ken, we have received your inquiry below. What's your firm deadline? Is that your only request, or do you have more specific questions of the agency? Thank you. Sierra Club v. EPA 18cv3472 NDCA Tier 13 ED 002061 00011139-00001 > > Ms. Latham: > I am a pharmacist and contributor to the journal "Pharmacy Times". I'm composing an article on pharmaceuticals in waste water as a result of human consumption of medications and suggesting more awareness on the part of pharmacists and consumers. > Some of my research suggests that only about 50% of pharmaceuticals or the metabolites in waste water is removed by waste water treatment plant technology. This waste ultimately finds its way into our drinking water at low levels. > So, efforts by consumers to choose medications with high absorptive and low active excretion rates would be beneficial and lower your personal "pharmaceutical footprint". > Would you be able to provide me with a supporting quote or concern for my publication on behalf of the EPA? > Respectfully, > Ken Fagerman, R.Ph.,M.M. > Sierra Club v. EPA 18cv3472 NDCA Tier 13 ED 002061 00011139-00002